Use of a Desensitization Protocol in a Patient with Brentuximab Hypersensitivity: A Case Report from a Hospital in Rancagua, Chile.

Hypersensitivity reactions to antineoplastic agents may jeopardize treatment continuity. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, may elicit hypersensitivity reactions that require specific management strategies. Case: A 19-year-old male with refractory Hodgkin lymphoma developed significant hypersensitivity to brentuximab during prior cycles. A 12-step rapid desensitization protocol with standardized premedication and close monitoring was implemented. Two hypersensitivity-like events occurred during infusion and were controlled with supportive measures and temporary infusion rate adjustments. The protocol enabled delivery of the full planned dose and continuation of therapy.

Conclusions

Rapid desensitization to brentuximab is a safe and feasible strategy to maintain treatment efficacy in hypersensitive patients when performed with standardized pharmacy preparation, premedication, and careful clinical surveillance.